23andMe (NASDAQ:ME), Inc. (NASDAQ:ME) is a California-based biotechnology company specializing in direct-to-consumer genetic testing and personalized genomics. Founded in 2006 and headquartered in Sunnyvale, the company offers at-home DNA collection kits that enable individuals to gain insights into their ancestry, inherited traits and potential health predispositions. Through a simple saliva sample submitted via mail, customers receive a comprehensive report detailing genetic ancestry composition, carrier status for specific conditions, wellness traits and pharmacogenetic information.
In addition to its consumer-facing services, 23andMe operates a research platform that aggregates de-identified genetic and survey data to advance drug discovery and genetic research. The company has forged partnerships with leading pharmaceutical and academic institutions, leveraging its growing database—one of the world’s largest collections of individual genotypes—to identify novel therapeutic targets. Through these collaborations, 23andMe seeks to bridge consumer genomics with precision medicine, accelerating the development of treatments for conditions such as Parkinson’s disease and autoimmune disorders.
23andMe serves customers across multiple regions, including the United States, Canada, the United Kingdom, select countries in Europe, Australia and New Zealand. Its products are distributed online through the company’s website and via select retail partners. The platform’s user-friendly interface allows customers to explore ancestry timelines, DNA relatives and health-risk reports, while optional subscription services provide ongoing updates and access to new features as genetics research evolves.
The company was co-founded by Linda Avey, Paul Cusenza and Anne Wojcicki, who continues to serve as Chief Executive Officer. Under her leadership, 23andMe went public in June 2021 through a merger with a special purpose acquisition company (SPAC), fueling investments in research and global expansion. Guided by a board of experienced biotech investors and scientists, 23andMe remains focused on empowering consumers with actionable genetic insights and advancing human health through data-driven discovery.
